<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074165</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00000641</org_study_id>
    <secondary_id>5R01CA137488-15</secondary_id>
    <secondary_id>ONC-02059-LX</secondary_id>
    <secondary_id>641</secondary_id>
    <secondary_id>7465</secondary_id>
    <secondary_id>OHSU-641</secondary_id>
    <nct_id>NCT00074165</nct_id>
    <nct_alias>NCT00261651</nct_alias>
  </id_info>
  <brief_title>Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen</brief_title>
  <official_title>A Phase II Trial Involving Patients With Recurrent PCNSL Treated With Carboplatin/BBBD, by Adding Rituxan (Rituximab), An Anti CD-20 Antibody, To The Treatment Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OHSU Knight Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>OHSU Knight Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill
      them or deliver cancer-killing substances to them without harming normal cells. Drugs used in
      chemotherapy, such as carboplatin, cyclophosphamide, etoposide, etoposide phosphate, and
      cytarabine, use different ways to stop cancer cells from dividing so they stop growing or
      die. Osmotic blood-brain barrier disruption uses certain drugs to open the blood vessels
      around the brain and allow anticancer substances to be delivered directly to the brain tumor.
      Chemoprotective drugs such as sodium thiosulfate may protect normal cells from the side
      effects of carboplatin-based chemotherapy. Combining rituximab with chemotherapy given with
      osmotic blood-brain barrier disruption plus sodium thiosulfate may kill more cancer cells.

      PURPOSE: Phase II trial to study the effectiveness of combining rituximab with combination
      chemotherapy given with osmotic blood-brain barrier disruption plus sodium thiosulfate in
      treating patients who have refractory or recurrent primary CNS lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the efficacy of rituximab, carboplatin, cyclophosphamide, etoposide or
           etoposide phosphate and cytarabine administered in conjunction with osmotic blood-brain
           barrier disruption and high-dose sodium thiosulfate, in terms of complete response rate,
           in patients with refractory or recurrent primary CNS lymphoma.

      Secondary

        -  Determine the overall survival and 2-year progression-free survival of patients treated
           with this regimen.

        -  Determine the quality of life and cognitive function of patients treated with this
           regimen.

        -  Determine the neurotoxicity of this regimen in these patients.

        -  Determine the percentage of patients with ototoxicity over time after treatment with
           this regimen.

        -  Determine the effect of delayed administration of sodium thiosulfate on granulocyte and
           erythrocyte counts in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive rituximab IV on day 1. On days 2 and 3, patients receive carboplatin
      intra-arterially over 10 minutes, cyclophosphamide IV over 10 minutes, and etoposide or
      etoposide phosphate IV over 10 minutes in conjunction with blood-brain barrier disruption.
      Patients also receive high-dose sodium thiosulfate IV over 15 minutes administered 4 and 8
      hours after carboplatin on days 2 and 3 and intraventricular or intrathecal cytarabine on day
      14. Beginning 48 hours after the last dose of chemotherapy, patients receive filgrastim
      (G-CSF)* subcutaneously (SC) daily for 7-10 days or until blood counts recover. Treatment
      repeats every 4 weeks for up to 12 courses.

      NOTE: * Alternatively, patients may receive a single dose of pegfilgrastim SC, administered
      48 hours after the completion of chemotherapy

      Patients with intraocular lymphoma also receive methotrexate intravitreally twice weekly
      until the vitreous is clear of cells by slit lamp exam; once weekly for 1 month; and then
      monthly for 1 year.

      Quality of life is assessed at baseline, every 3 months during treatment, within 30 days of
      final treatment, then every 6 months for 1 year, and then annually thereafter.

      Patients are followed monthly for 3 months, every 2 months for 8 months, every 3 months for 1
      year, and then every 6 months thereafter.

      PROJECTED ACCRUAL: A total of 11-25 patients will be accrued for this study within 7-10
      years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of accrual
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.</measure>
    <time_frame>2 years</time_frame>
    <description>Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <condition>Lymphoma</condition>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>All subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituxan</intervention_name>
    <description>Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>Rituximab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide phosphate</intervention_name>
    <description>Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium thiosulfate</intervention_name>
    <description>Dose: 4 hrs post carboplatin = 20gm/m2;
Dose: 8 hrs post carboplatin = 16gm/m2
Infused IV x 2 days</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>STS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neupogen</intervention_name>
    <description>48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neulasta</intervention_name>
    <description>Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.</description>
    <arm_group_label>All subjects</arm_group_label>
    <other_name>Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Dose: 40mg on Day 14 following chemotherapy</description>
    <arm_group_label>All subjects</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Signed informed consent form in accordance with institutional guidelines

          -  Histologically or cytologically confirmed primary CNS lymphoma documented by brain
             biopsy or cerebrospinal fluid or vitrectomy analysis

          -  CD20 positive disease

          -  Progressive or relapsed disease during or after completion of prior methotrexate-based
             chemotherapy

          -  Aged 18 months to 75 years

          -  Performance status ECOG 0-3 OR Karnofsky 30-100%

          -  Hematocrit at least 25% (transfusion or epoetin alfa allowed)

          -  Absolute granulocyte count at least 1,200/mm^3

          -  Platelet count at least 100,000/mm^3 OR at least lower limit of normal

          -  Bilirubin no greater than 2.0 times upper limit of normal

          -  Creatinine less than 1.8 mg/dL

          -  Calculated Creatinine clearance (CrCl) at least 50 mL/min

          -  Adequate cardiac function to tolerate general anesthesia

          -  Adequate pulmonary function to tolerate general anesthesia

          -  Available for follow-up for 1 year post therapy

          -  Fertile patients must use effective contraception for a minimum of 2 months before and
             during study participation

        EXCLUSION CRITERIA:

          -  Radiographic signs of intra-cranial herniation and/or spinal block

          -  HIV positive

          -  Systemic lymphoma

          -  Positive serum HCG, pregnant or lactating

          -  Allergy to study agents

          -  Hepatitis B or hepatitis C positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward A. Neuwelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OHSU Knight Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Good Samaritan Hospital Cancer Treatment Center, Hatton Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Knight Cancer Institute at Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <results_first_submitted>October 10, 2011</results_first_submitted>
  <results_first_submitted_qc>October 10, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 16, 2011</results_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>OHSU Knight Cancer Institute</investigator_affiliation>
    <investigator_full_name>Edward Neuwelt</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <keyword>thrombocytopenia</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>primary central nervous system Hodgkin lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Sodium thiosulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rituximab and Carboplatin</title>
          <description>Rituximab: (i.v.) 375 mg/m^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m^2 /day x 2 days = 400 mg/m^2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab and Carboplatin</title>
          <description>Rituximab: (i.v.) 375 mg/m^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m^2 /day x 2 days = 400 mg/m^2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.235" spread="12.799"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.</title>
        <description>Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Carboplatin</title>
            <description>Rituximab: (i.v.) 375 mg/m^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m^2 /day x 2 days = 400 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Complete Response Rate to Chemotherapy Regimen Assessed by Radiographic Response at 2 Years.</title>
          <description>Per RECIST criteria (v1.1) and assessed by magnetic resonance imaging (MRI): Complete response (CR), Disappearance of all target lesions.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response</title>
        <description>Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.</description>
        <time_frame>5 years</time_frame>
        <population>Inadequate sample size to determine overall survival</population>
        <group_list>
          <group group_id="O1">
            <title>Rituximab and Carboplatin</title>
            <description>Rituximab: (i.v.) 375 mg/m^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m^2 /day x 2 days = 400 mg/m^2</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Overall Survival Assessed by Clinical and Radiographic Response</title>
          <description>Overall survival is measured from entry onto study until death from any cause or until death or progression of disease, respectively.</description>
          <population>Inadequate sample size to determine overall survival</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival Assessed by Clinical and Radiographic Response From First Day of Treatment Until Tumor Progression</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessed by EORTC QOL Before Treatment and Then Every 3 Months</title>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ototoxicity Assessed by Audiology Hearing Test Done Monthly During Treatment</title>
        <time_frame>2 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Sodium Thiosulfate (STS) on Granulocytes and Erythrocytes Assessed by Complete Blood Count Lab Values Done Weekly During Treatment</title>
        <time_frame>2 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Rituximab and Carboplatin</title>
          <description>Rituximab: (i.v.) 375 mg/m^2 given the evening before blood brain barrier disruption(BBBD) procedure day 1 Carboplatin: (i.a.) 200 mg/m^2 /day x 2 days = 400 mg/m^2</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Carotid Artery Tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance and Increased Blood Sodium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Unresponsiveness</sub_title>
                <description>Hospitalized for unresponsiveness</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hospitalized for Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Extended Hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Superficial Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Neurological Symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Chemical Meningitis and Seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Leg Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edward Neuwelt</name_or_title>
      <organization>OHSU Knight Cancer Institute</organization>
      <phone>503-494-5626</phone>
      <email>neuwelte@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

